Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist
Phase 3Terminated 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Nausea and Vomiting
Conditions
Chemotherapy-induced Nausea and Vomiting
Trial Timeline
Sep 14, 2015 โ Feb 24, 2017
NCT ID
NCT02519842About Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist is a phase 3 stage product being developed by Merck for Chemotherapy-induced Nausea and Vomiting. The current trial status is terminated. This product is registered under clinical trial identifier NCT02519842. Target conditions include Chemotherapy-induced Nausea and Vomiting.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02519842 | Phase 3 | Terminated |
Competing Products
20 competing products in Chemotherapy-induced Nausea and Vomiting